The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1656
ISSUE 1656
August 8, 2022
Issue 1656
- COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine
- COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (online only)
- COVID-19 Update: Prescription of Paxlovid by Pharmacists (online only)
- Tapinarof Cream (Vtama) for Psoriasis
- Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
- Lumateperone (Caplyta) for Bipolar Depression
- A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine
August 8, 2022 (Issue: 1656)
The FDA has issued an Emergency Use Authorization
(EUA) for an adjuvanted protein subunit COVID-19
vaccine manufactured by Novavax. The vaccine
is indicated for use as a two-dose primary series
to prevent COVID-19 in adults; it is not...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.